Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 6/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | GALR1 | P47211 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17033314 | 1.00 | CA1 (0.55) | CA1CA2ALDH1A1MEN1KMT2A | |
| SCHEMBL20992166 | 0.81 | CA1 (0.43) | CA1CA2ALDH1A1HTR2CGALR1 | |
| SCHEMBL17050161 | 0.81 | CA2 (0.43) | CA1CA2ALDH1A1HTR2CACHE | |
| SCHEMBL21134648 | 0.79 | CA1 (0.41) | CA1CA2ALDH1A1HTR2CFAAH | |
| SCHEMBL17031837 | 0.79 | CA1 (0.41) | CA1CA2ALDH1A1HTR2CFAAH | |
| SCHEMBL19234729 | 0.75 | CA1 (0.38) | CA1CA2HTR2C | |
| SCHEMBL20878311 | 0.74 | CA1 (0.38) | CA1CA2HTR2CADRA1D | |
| SCHEMBL24090474 | 0.73 | ADRA1D (0.38) | CA1CA2ALDH1A1ADRA1D | |
| SCHEMBL12900511 | 0.73 | ADRA1D (0.38) | CA1CA2ALDH1A1ADRA1D | |
| SCHEMBL12651546 | 0.73 | ADRA1D (0.38) | CA1CA2ALDH1A1ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550140-B2 | Ether compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190048033-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550140-B2 | Ether compounds for treatment of complement mediated disorders | TFPI, CFD, C9 | CA1 3111/4885CA2 4172/4885ALDH1A1 2728/4885 |
| US-20190048033-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, C9 | CA1 3111/4885CA2 4172/4885ALDH1A1 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.